Thomas E. Hutchinson, a Strategic Advisor for EBG Advisors, Inc., was quoted in Inside CMS, in “CMS Accounts for Costly Hep C Rx; Part D Premiums Expected to Rise,” by John Wilkerson.
Following is an excerpt:
Thomas Hutchinson, an adviser at Epstein Becker & Green, said CMS added hepatitis C drug costs to its model that adjusts for risk to account for the high cost to plans. He said it’s common for CMS to update the Part D risk model, but he thinks this is the first time the agency focused that update on hepatitis C. …
“The biggest impact in 2016 may be felt by Part D beneficiaries as the Advance Notice highlights increased drug expenses, signaling that Part D premiums will likely be on the rise for the coming plan year,” Hutchinson writes in a post on Epstein, Becker & Green’s website.